Compass Therapeutics, Inc.

NASDAQ:CMPX

Biotechnology

Healthcare
$0.61 -1.46%

-$0.03 today

Market cap
$109.26M
Beta
0.74
P/E (TTM)
-5.5
EPS (TTM)
-$0.37
52W Low $1.61High $6.88

Volume 2.90M

Average 7.64M

Returns on capital

Compass Therapeutics, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-33.8%

avg -22.7%

ROIC

-35.3%

avg -55.2%

ROA

-30.3%

avg -49.5%

Analysis

ROA is currently the strongest return metric at -30.3% versus its period average of -49.5%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Thomas J. Schuetz

Chief Executive Officer & Vice ChairmanUSD 1.03M656.60M4.78%

Barry Shin

Chief Financial OfficerUSD 717K54525.00K0.38%

Jonathan Anderman

Senior Vice President, General Counsel & Corporate SecretaryUSD 648K43196.00K0.14%

Bing Gong

Chief Scientific OfficerUSD 445.5K50——

Anna Gifford

Senior Manager of Communications & Chief of Staff————

Cynthia A. Sirard

Chief Medical Officer—56——

James Kranz

Vice President and Head of Chemistry Manufacturing & Controls————

Arjun Prasad

Chief Commercial Officer—480<0.01%

Neil L. Lerner

Senior Vice President & Chief Accounting Officer—59——

Karin Herrera

Senior Vice President & Head of Clinical Operations————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Apr 29, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

4

$96,850.00

Sells

0

$0.00

Net Transaction Value

+$96,850.00

Net buying

Most Active

Lerner Neil

3 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Oct 1, 26

Lerner Neil

Direct

Buy$18.4K
Sep 24, 26

Lerner Neil

Direct

Buy$2.8K
Apr 29, 26

Lerner Neil

Direct

Buy$28.4K
Apr 29, 26

Anderman Jonathan

Direct

Buy$47.3K

Summary

Insiders reported 4 buys worth $96,850.00 and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $96,850.00. Lerner Neil was the most active insider with 3 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A11 analysts
RevenueN/AN/AN/A
N/A12 analysts
Net IncomeN/AN/AN/A
N/A12 analysts
EBITN/AN/AN/A
N/A12 analysts

Analysis

Analysis will appear once historical growth or forward estimates are available for this company.

Competitors

Who does Compass Therapeutics, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about CMPX's management, answered from reported figures.

Who manages CMPX?

Compass Therapeutics, Inc. (CMPX) lists 10 active executives. The top listed executive is Anna Gifford, Senior Manager of Communications & Chief of Staff.

Are CMPX insiders buying or selling?

Recent insider activity shows net buying of $140.61M.